Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
Authors
Keywords
-
Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-12-13
DOI
10.1002/jlb.5ma1119-265r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
- (2018) Hans H. Oberg et al. Frontiers in Immunology
- Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells
- (2018) Sonja Lieber et al. OncoImmunology
- Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
- (2018) Emelie Rådestad et al. OncoImmunology
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity
- (2017) Guranda Chitadze et al. TRENDS IN IMMUNOLOGY
- The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
- (2017) Thomas Worzfeld et al. Frontiers in Oncology
- Tumor microenvironment: The culprit for ovarian cancer metastasis?
- (2016) Zhongyue Luo et al. CANCER LETTERS
- Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
- (2016) Hans-Heinrich Oberg et al. PANCREATOLOGY
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells
- (2014) H.-H. Oberg et al. CANCER RESEARCH
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
- (2014) Hans-Heinrich Oberg et al. Frontiers in Immunology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- CD1d-lipid antigen recognition by the γδ TCR
- (2013) Adam P Uldrich et al. NATURE IMMUNOLOGY
- Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation
- (2013) BEI ZHANG et al. ONCOLOGY REPORTS
- Identification of Ovarian Cancer Metastatic miRNAs
- (2013) Souriya Vang et al. PLoS One
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
- (2012) P Glorius et al. LEUKEMIA
- Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes
- (2011) Dongmei Lai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- (2009) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
- (2008) Alessandro D. Santin et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now